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Based on a series of clinical trials showing no
difference in the effectiveness or tolerability of most major
classes of antihypertensive medications, the Joint National
Commission on High Blood Pressure Treatment recommends




-blockers or diuretics as initial
hypertensive therapy unless there are compelling indications
for another type of medication. Nevertheless, many physicians
continue to favor more expensive medications like angiotensin-
converting enzyme (ACE) inhibitors and calcium channel
blockers as first line agents. The persistent use of these agents
raises questions as to whether physicians perceive ACE inhib-









We surveyed 1,200 primary care physicians in 1997,
and another 500 primary care physicians in 2000, and asked
them to estimate the relative effectiveness and side effects
of 4 classes of medication in treating a hypothetical patient





calcium channel blockers, and diuretics. In addition, we asked
them to indicate whether they ever provided free samples of




Perceptions of the relative effectiveness and side
effects of the 4 classes of hypertension medications did not
significantly change over the 3 years, nor did prescription rec-
ommendations. Physicians perceive that diuretics are less













-blockers are less tolerated








 .001). In a multivariate model,
perceptions of effectiveness and tolerability displayed signifi-
cant associations with prescription preference independent of
background variables. The only other variable to contribute





Despite numerous clinical trials showing no
difference in the effectiveness or side-effect profiles of these
4 classes of drugs, most physicians believed that diuretics were




-blockers were less tolerated than other
medications. Moreover, their prescription practices were
associated with their provision of free samples provided by
pharmaceutical representatives, even after adjusting for other





-blockers and diuretics may need to be directed
at overcoming misunderstandings about the effectiveness and




hypertension treatment; physician survey;
pharmaceutical promotion. 
 




eta blockers and diuretics are inexpensive, effective,
and well-tolerated antihypertensive medications. They
are recommended as first line agents for the treatment of
uncomplicated hypertension by the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment




 A number of randomized controlled




-blockers and diuretics are as effective
at lowering blood pressure as newer, more expensive agents





 Moreover, a number of rand-





are equally tolerated or better tolerated than ACE inhibitors









and diuretics has declined steadily in the past 15 years in









and diuretic use is related to misperceptions among phy-
sicians about their efficacy and tolerability. Specifically,





diuretics as first line agents because they believe, contrary
to published reports, that these medications are either less
effective or less tolerated than newer, more expensive med-
ications. Physicians may also preferentially prescribe
newer medications because these agents are actively pro-
moted by pharmaceutical companies, whose sales repre-





 or might influence prescribing





 To date, we know of no studies
assessing physicians’ perceptions of the effectiveness and
tolerability of antihypertensive medications, nor any stud-
ies that explore the relationship between availability of
pharmaceutical samples and physicians’ beliefs and prac-
tices about antihypertensive medications.
We surveyed primary care physicians in the United
States in 1997 to determine their beliefs about the relative





calcium channel blockers, and diuretics, and to see whether
these beliefs were associated with physicians’ self-reported
willingness to prescribe each class of medications as first
line therapy for uncomplicated hypertension. In addition,
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we explored the relationship between provision of free phar-
maceutical samples to patients and attitudes and practices
toward these 4 classes of antihypertensive medications. The
1997 survey was conducted shortly after circulation of the




-blockers and diuretics as first line agents. Given the short
time between circulation of the JNC report and circulation
of our survey, we repeated the survey in 2000 (with minor
modifications described below) to learn how attitudes and





We conducted an anonymous mail survey of primary care
physicians in the United States (general internists, family
medicine specialists, and general practitioners), randomly
selected from the AMA master file, the most comprehensive
mailing list of U.S. physicians, that includes both members
of the AMA and nonmembers. We mailed questionnaires
to 1,200 physicians in 1997 and 500 physicians in 2000.
We included a small incentive in the first mailing ($1 in
1997 and $2 in 2000) and mailed a second instrument,





We Asked Physicians to Consider the Following Vignette.
 
A 55-year-old white male presents to you with a BP = 170/
105. He has no other medical problems, is on no medica-
tions, and has completed a 1-year trial of diet and exercise
to control his hypertension, but his BP remains elevated.
 
Effectiveness, Tolerability, and Prescription Recommenda-
tions.
 
Physicians were asked to estimate the effectiveness





blockers, and diuretics in this type of patient:
 
“In your experience, what percent of the time will each of
the following drugs (as monotherapy) achieve a normal
blood pressure (< 140/90) in patients like this?
In your experience, what percent of the time do patients
like this have to discontinue each of the following drugs
due to side effects?”
 
Physicians were then asked what medication or class
of medication they would prescribe for this patient as initial
monotherapy. They were told that their choice was not
limited to the 4 classes of medications listed. In the 1997
survey, 19% of physicians recommended more than 1 medi-
cation. The instructions were revised in 2000 to emphasize
that we wanted them to list the first medication or class




Physicians were then asked to rate the importance of
several factors in their choice of antihypertensive agent “in
patients without other medical problems.” The factors were
cost, number of doses per day, likelihood of achieving
normal blood pressure with monotherapy, side effects,
prevention of stroke or heart attack, and availability of free
samples. Subjects rated the importance of each factor on





After answering the questions described above, physi-
cians provided basic demographic information, including
age and gender, and answered a set of questions about
their practice. Physicians were also asked, “Do you ever
provide patients free sample medications from pharma-
ceutical representatives to treat their high blood pressure?”
with a response mode of yes or no.
 
Randomization Scheme for the 1997 Survey
 
In the 1997 survey, we randomized physicians to 1 of
2 questionnaire versions, out of concern that asking
physicians to rate the effectiveness and tolerability of the
4 classes of medications would influence their ensuing
prescription recommendations. One group of physicians
provided a prescription recommendation without providing
effectiveness and tolerability estimates, and a second group
responded to all 3 types of questions. We found no differ-
ences in prescription recommendations based on question-
naire version. Thus we include data from both groups.
Because of this randomization scheme, the number of





We tested for differences in survey responses across











 tests for continuous varia-
bles. Responses to the 4 questions about effectiveness were
significantly lower in 2000 than in 1997. When the effec-
tiveness data were normalized, however (i.e., converted to
deviations from the subject’s mean effectiveness rating
across all 4 classes of medication), differences became non-
significant, indicating that beliefs about the effectiveness
of each class of medication relative to the other 3 classes
did not change significantly from 1997 to 2000. Of the other
21 variables examined, a significant difference between





 = .027). This is what would be expected by chance. Sub-
sequent analyses therefore pooled data from these 2 years.
One-way repeated-measures analyses of variance were
used to test differences in: 1) perceived effectiveness of the
4 classes of medication; 2) perceived tolerability of the 4
classes of medication; and 3) perceived importance of var-
ious factors on prescription preference. Within each of
these 3 sets of variables, differences between specific sub-








(Contrasts are specific linear combinations of variables;
they are used in multivariate analysis to test whether cer-
tain subsets of variables are associated in expected ways.
Difference contrasts were used here because they allow a
test of whether scores on one variable differ significantly
from the mean of all other variables in the set, e.g., whether
physicians think diuretics are less effective than the other












 tests for continuous variables) were also used to
identify 1) differences in perceived effectiveness and toler-
ability between the class of medication preferred by the
respondent and the other classes; 2) differences in back-
ground characteristics between physicians who did not
offer patients free samples and those who did; and 3) fac-
tors associated with prescription recommendations. In
addition, 2 logistic regressions of prescription recommen-
dations (coded as 0 for those who prescribed ACE inhibitors




-blockers or diuretics) were performed. In the first, the
predictors were the variables representing perceived effec-
tiveness and tolerability of each class of medication; as
described above, these were continuous variables, denoting
respondents’ estimates of the percentages of patients who
would achieve normal blood pressure with that class of
medication, or discontinue it due to side effects. In the sec-
ond logistic regression, the predictors were the perceived
effectiveness and tolerability variables plus age, sex, and
all other background variables that displayed bivariate





Of the 647 subjects, 81 (12.5%) indicated more than
1 class of drug on the prescription preference item. As indi-
cated earlier, 74 of these were physicians who responded
to the 1997 survey. These 81 subjects were excluded from
all analyses involving prescription preference. We com-
pared these subjects to the rest of the sample on all survey





 < .05) were found on 2—perceived




 = .03), and








Of the 1,700 questionnaires mailed, 64 were undeliv-
erable because of bad addresses, and 17 were returned
blank with valid reasons for nonresponse (e.g., deceased,
not a generalist, not in practice), leaving 1,619. We received
completed questionnaires from 670 physicians for an over-
all response rate of 41%. Sixteen subjects were excluded
because they indicated they had subspecialty training and
7 others because they indicated they were not in practice,
leaving a final sample of 647 respondents. Physicians’
characteristics are shown in Table 1.
 
Perceived Effectiveness and Tolerability of 
Antihypertensive Agents
 
Table 2 shows physicians’ perceptions of the effective-
ness and tolerability of the 4 classes of antihypertensive
Table 1. Physicians’ Characteristics
 
Characteristic Value
Age, mean (SD) 46.6 (11.2)
Male, % 75.7
Years in practice, mean (SD) 18.7 (11.7)
Specialty, %
General internal medicine 47.3
Family medicine 51.3
Other generalist 1.4








Hours per week in patient care, mean (SD) 44.3 (17.2)
Provide samples, % 86.4
Percent of patients in managed 42.6 (30.0)
care, mean (SD)
* Percentages do not add up to 100% because subjects could choose
multiple categories.





Mean (SD) (N = 443)‡
Perceived Likelihood of 
Side Effects†, 
Mean (SD) (N = 438)‡
Physicians Recommending a Medication 
from This Class as First Line Agent, % 
(N = 537)§
ACE inhibitor 55.9 (25.9) 13.5 (10.8) 37.6
β-blocker 54.1 (25.2) 21.9 (15.4) 28.7
Calcium channel blocker 55.1 (25.9) 14.7 (11.1) 11.0
Diuretic 37.0 (25.2) 12.5 (12.0) 18.4
* Percent chance of hypothetical patient achieving blood pressure less than 140/90.
† Percent chance of hypothetical patient discontinuing due to side effects.
‡ Subjects who were not asked the effectiveness and tolerability questions (n = 195) are excluded.
§ Subjects who chose more than 1 class of medication (n = 81) and subjects who gave no choice (n = 29) are excluded. Percentages do not
add up to 100% because 4.3% of subjects chose a medication not in the 4 specified classes.












agents. Perceived effectiveness differed significantly










 < .001). The mean perceived
effectiveness of diuretics was significantly lower than the











 < .001). Mean perceived tolerability
















was significantly lower than the mean tolerability of














Table 2 also shows which class of medications physi-
cians stated they would prescribe for the hypothetical
patient. Thirty-eight percent of physicians recommended




-blockers, 18% recommended diuretics, and 11% recom-
mended calcium channel blockers. The remaining 4%
chose medications not in these 4 classes.
 
Factors Perceived to Influence Choice of 
Antihypertensive Medication
 
Table 3 shows physicians’ self-reports of the impor-
tance various factors play in influencing their choice of
antihypertensive medication in patients with no other
medical problems. Perceived importance differed signifi-










 < .001). Per-
ceived importance of the availability of free samples was
significantly lower than the mean importance of the other












Factors Empirically Associated with Choice of 
Antihypertensive Medication
 
As described earlier, we performed bivariate analyses
to identify factors actually associated with prescription
recommendations (as distinct from factors perceived by
physicians to be important). Prescription recommendations
were associated with the perceived effectiveness and toler-
ability of antihypertensive medications. The mean per-
ceived effectiveness of the recommended medication was
significantly greater than the mean combined effectiveness









 < .001). The mean perceived likelihood of side
effects was significantly lower for recommended medica-








 = .003). As shown in Table 4, subjects who recommended
ACE inhibitors or calcium channel blockers perceived those
classes of medication to be significantly more effective than









-blockers and diuretics to have a
higher likelihood of side effects. A logistic regression of pre-
scription preference (coded as 0 for those who prescribed





-blockers or diuretics) on physicians’
perceptions of effectiveness and tolerability was highly
Table 3. Self-reported Importance of Factors Influencing 






Prevention of stroke or heart attack 4.2 (0.8)
Likelihood of side effects 4.1 (0.7)
Number of doses per day 4.0 (0.7)




Availability of free samples 2.5 (1.2)
* Mean importance rating on a scale from 1 for not at all important
to 5 for extremely important.
Table 4. Perceived Effectiveness and Tolerability of Antihypertensive Agents by Prescription Choice
 
Physicians Prescribing ACE Inhibitor 
or Calcium Channel Blocker 
(N = 190)*
Physicians Prescribing 
β-blocker or Diuretic 
(N = 176)*
P Value for Comparison 
Between Physician Groups
Effectiveness Mean (SD) percent of time drug
expected to be effective
ACE inhibitor 62 (23) 49 (27) <.001
β-blocker 53 (26) 55 (24) .46
Calcium channel blocker 58 (24) 51 (27) .006
Diuretic 35 (23) 39 (26) .12
Side effects Mean (SD) percent of time drug
expected to be discontinued due to side effects
ACE inhibitor 13 (11) 13 (11) .68
β-blocker 24 (16) 19 (14) .006
Calcium channel blocker 14 (9) 14 (12) .85
Diuretic 14 (13) 10 (10) .002
* Subjects who were not asked the effectiveness and tolerability questions, chose more than 1 class of medication, chose a medication not in
the 4 specified classes, or gave no choice are excluded.
ACE, angiotensin-converting enzyme inhibitor.
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significant (χ2 = 84.0, P < .001). All predictors contributed
significantly to the model except for the perceived likelihood
of side effects with ACE inhibitors (see Table 5).
Table 6 presents the bivariate associations of prescrip-
tion preference with the background variables measured
in this study. Subjects who recommended ACE inhibitors
or calcium channel blockers were significantly more likely
to be in solo practice and private practice settings, and less
likely to be in “other” practice settings (i.e., not private, public,
or academic), than were subjects who recommended β-
blockers or diuretics; they also reported more hours per
week spent in patient care, and more years in practice.
Finally, they were significantly more likely to report pro-
viding their patients with free samples of antihypertensive
medications provided by pharmaceutical companies.
To assess the association of perceived effectiveness and
tolerability with prescription preference independent of
background variables, we performed a multivariate logistic
regression of prescription recommendations (coded as 0 for
those who prescribed ACE inhibitors or calcium channel
blockers and 1 for those who prescribed β-blockers or
diuretics), using the following variables as predictors: 1) the
8 variables denoting perceived effectiveness and tolerability
of the 4 classes of drug; 2) the 2 demographic variables
measured in the study (age and sex); and 3) all other back-
ground variables that displayed bivariate associations
with prescription recommendations at P < .10—that is,
hours per week spent in patient care, years in practice,
and dichotomous variables indicating solo practice, private
practice setting, other practice setting, and provision of
samples. The results are shown in Table 7. The overall
model was significant (χ2 = 104.7, P < .001). Of the 8 vari-
ables denoting perceived effectiveness and tolerability, all
contributed significantly (P ≤ .012) except perceived toler-
ability of ACE inhibitors and β-blockers. The only other
variable to contribute significantly to the model was pro-
vision of samples (P = .001).
Overall, 86% of physicians said they offered samples to
their patients. Physicians using samples spent more hours
per week in patient care (45.6 vs 36.2; t = 4.84, P < .001),
reported having a lower percentage of managed care patients
(39.2% vs 63.9%; t = 5.37, P < .001), were more likely to
practice family medicine (54% vs 34%; χ2 = 11.55, P = .003),
were more likely to be in private practice (78% vs 22%;
Table 5. Adjusted Odds Ratio for Perceptions as Predictors 
of Prescription Choices*
 
Predictor Odds Ratio P Value
Effectiveness of ACE inhibitors† 0.96 <.001
Effectiveness of β-blockers† 1.05 <.001
Effectiveness of calcium channel 
blockers†
0.98 .009
Effectiveness of diuretics† 1.02 .014
Side effects of ACE inhibitors‡ 0.99 .369
Side effects of β-blockers‡ 0.98 .038
Side effects of calcium channel 
blockers‡
1.04 .016
Side effects of diuretics‡ 0.97 .022
* Prescription choice coded as 0 for those who prescribed ACE
inhibitors or calcium channel blockers and 1 for those who prescribed
β-blockers or diuretics. Subjects who chose more than 1 class of
medication (n = 81), chose a medication not in the 4 specified classes
(n = 23), or made no choice (n = 29) are excluded.
† Percent chance of hypothetical patient achieving blood pressure less
than 140/90.
‡ Percent chance of hypothetical patient discontinuing due to side
effects.
ACE, angiotensin-converting enzyme inhibitor.
Table 6. Physicians’ Characteristics by Prescription Choice
 
Characteristic
Value Among Physicians Prescribing 
P Value for Comparison 
Between Physician Groups




or Diuretic (N = 253)*
Age, mean (SD) 47.1 (11.0) 46.3 (11.3) .39
Sex, % male 77.8 74.1 .33
Years in practice, mean (SD) 19.7 (11.6) 17.9 (11.7) .09
Specialty, % in family medicine 52.1 51.4 .87
Type of practice, % solo 34.6 22.1 .002
Practice setting, % in:†
Private practice 75.3 64.1 .006
Public practice 9.7 11.2 .58
Academic 13.5 15.1 .60
Other 9.7 15.9 .03
Hours per week in patient care, mean (SD) 46.1 (18.5) 41.7 (16.0) .005
Provide samples, % 91.9 78.9 <.001
Percent of patients in managed care, 43.9 (29.2) 43.2 (31.4) .78
mean (SD)
* Subjects who chose more than 1 class of medication (n = 81), chose a medication not in the 4 specified classes (n = 23), or made no choice
(n = 29) are excluded.
† Percentages do not add up to 100% because subjects could choose multiple categories.
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χ2 = 114.76, P < .001), and were more likely to be male
(77% vs 65%; χ2 = 6.01, P = .02). Age and number of years
in practice did not differ among physicians according
to whether they provided free samples (P = .32 and .77,
respectively). Perceptions of the effectiveness and toler-
ability of antihypertensive medications also differed little
among physicians who did and did not offer free samples.
Compared to physicians not using samples, physicians
using samples perceived ACE inhibitors to be more effective
(56.9% efficacy vs 48.2%; t = 2.15, P = .04), and also
displayed a marginally significant tendency to perceive
diuretics to have a lower likelihood of side effects (12.12%
vs 15.95%; t = 1.86, P = .07), but the 2 groups did not differ
significantly on perceived effectiveness or tolerability of the
other classes of medication (P = .21 to .99).
DISCUSSION
In this study, we explored physicians’ attitudes toward
antihypertensive medications in 1997, shortly after the
release of the JNC guidelines, and again in 2000. Attitudes
toward antihypertensive medications were consistent over
the 3-year period. Physicians believed that diuretics were
less effective than the other 3 classes of medication and
that β-blockers were less likely to be tolerated. We also
found that physicians who recommended β-blockers or
diuretics as first line agents were significantly less likely
than other physicians to provide free samples.
Why do many physicians recommend newer, more
expensive antihypertensive medications as first line agents
ahead of β-blockers and diuretics? Our data suggest that
physicians’ beliefs about the effectiveness and tolerability
of β-blockers and diuretics contribute to their unwilling-
ness to prescribe these agents. With so many medications
proven to be effective in treating high blood pressure, small
differences in the perceived effectiveness or tolerability of
medications may be all it takes for physicians to favor one
class of drugs over another. Why do physicians perceive
that β-blockers and diuretics are either not as effective or
not as well tolerated as other antihypertensive medications,
despite randomized controlled trial evidence to the con-
trary? Our study does not provide a definitive answer to
this question. Our study provides evidence that these pre-
scribing habits are associated with the practice of providing
sample medications, but that misperceptions about effec-
tiveness and side effects are not strongly related to whether
physicians provided free medication samples from phar-
maceutical representatives.12
Our study does not show whether the association
between the availability of free samples and physicians’
hypothetical prescribing habits is a causal relationship.
Physicians who provide free samples to patients may
already be less inclined to prescribe β-blockers and diu-
retics than are other physicians. Similarly, physicians who
prescribe β-blockers and diuretics may not give out sample
hypertension medications because samples of these inex-
pensive medications are not typically available. Neverthe-
less, medication samples have been shown to increase the
adoption rate of new drugs,22 and make physicians more
likely to prescribe expensive (rather than inexpensive)
medications.19,23
Our study has several limitations. First, we had a
response rate of 41%. Our results could have been influ-
enced by nonrespondent bias. However, the major findings
of this study were highly statistically significant, meaning
that nonresponse bias would have to have been extensive
to alter our major conclusions. Moreover, although the
response rate in the 2000 survey was substantially higher
than the 1997 survey (55% vs 36%), there were no significant
demographic or attitudinal differences between respondents
in 1997 and 2000. This suggests that increasing our overall
response rate to the 2000 level would not have substantially
influenced our results. Second, we observed only hypotheti-
cal prescription practices, not actual prescription practices.
However, research suggests that response to hypothetical
vignettes can be an accurate predictor of physicians’ actual
practices.24 Moreover, by using a clinical vignette we were
able to isolate physicians’ attitudes toward the treatment
of uncomplicated hypertension, a task that would have
been extremely difficult using a secondary database. Third,
we did not assess physicians’ interactions with pharma-
ceutical representatives, because pilot testing had shown
that such queries were not well received. The provision of
free drug samples is an imperfect proxy for physicians’
interactions with pharmaceutical representatives.
Table 7. Adjusted Odds Ratios for Physician Characteristics 
and Perceptions as Predictors of Prescription Choices*
 
Predictor† Odds Ratio P
Effectiveness of ACE inhibitors‡ 0.96 <.001
Effectiveness of β-blockers‡ 1.05 <.001
Effectiveness of calcium channel 
blockers‡
0.97 .006
Effectiveness of diuretics‡ 1.02 .010
Side effects of calcium channel 
blockers§
1.05 .006
Side effects of diuretics§ 0.96 .012
Provision of samples 0.18 .001
* Prescription choice coded as 0 for those who prescribed ACE
inhibitors or calcium channel blockers and 1 for those who prescribed
β-blockers or diuretics. Subjects who chose more than 1 class of
medication (n = 81), chose a medication not in the 4 specified classes
(n = 23), or made no choice (n = 29) are excluded. The analyses are
adjusted for perceived effectiveness and tolerability of the 4 classes
of drugs, age, gender, hours per week spent in patient care, years
in practice, practice setting, and provision of samples.
† Only those predictors that contributed to the model at P ≤ .10 are
shown.
‡ Percent chance of hypothetical patient achieving blood pressure less
than 140/90.
§ Percent chance of hypothetical patient discontinuing due to side
effects.
 Coded as 0 = no samples, 1 = samples.
ACE, angiotensin-converting enzyme inhibitor.
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CONCLUSION
Physicians perceive that diuretics are less effective than
other antihypertensive medications and that β-blockers are
less tolerated. In addition, their willingness to prescribe β-
blockers or diuretics is associated with whether they offer
free samples of medications from pharmaceutical repre-
sentatives, even after adjusting for demographic charac-
teristics, although it is impossible to determine from our
data whether this association is a causal relationship.
Efforts to increase the use of β-blockers and diuretics in
patients with uncomplicated hypertension may require
efforts to reeducate physicians about the effectiveness and
tolerability of β-blockers and diuretics.
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